Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer

References

• Ferlay J, Soerjomataram I, Bray F, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen B, Graf W, Pahlman L, Mahteme H. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol. 2008;15(3):745–753.
   Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–52316.
   PubMedGoogle Scholar
• American Cancer Society [webpage on the Internet]. Survival rates for stomach cancer by age; 2014. Available from: https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html. Accessed April 19, 2017.
   Google Scholar
• Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastroint Oncol. 2011;2(2):77–84.
   Google Scholar
• Kodera Y. Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? Nagoya J Med Sci. 2013;75(1–2):3–10.
   Web of Science ®Google Scholar
• Li Y, Zhou Y, Yang G, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22(30):6906–6916.
   Web of Science ®Google Scholar
• Elias D, Goéré D, Ducreux M, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 1990;50(2):332–340.
   Google Scholar
• Ni Z, Li C, Zhu Z, et al. Efficacy and safety of surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of advanced gastric cancer: a meta-analysis. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(12):1406–1413.
   Google Scholar
• Zeng W, Hu W, Li Y, et al. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14(1):29–37.
   Google Scholar
• Ji Z, Peng K, Li Y, et al. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–570.
   PubMed Web of Science ®Google Scholar
• Yang X, Huang C, Li Y, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6);1575–1581.
   Google Scholar
• Coccolini F, Cotte E, Ansaloni L, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1);12–26.
   Google Scholar
• Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(12):3972–3977.
   PubMed Web of Science ®Google Scholar
• Wu X, Yuan P, Ji J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tum Biol. 2013;34(1):463–469.
   PubMedGoogle Scholar
• Yuan M, Wang Z, Zhong H, et al. A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Mol Clin Oncol. 2016;5(2):395–399.
   Google Scholar
• Rudloff U, Langan R, Avital I, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275–284.
   PubMed Web of Science ®Google Scholar
• Zhibing W, Qinghua D, Ruzhen Z, et al. Clinical study of cisplatin hyperthermic intraperitoneal perfusion chemotherapy in combination with docetaxel, 5-flourouracil and leucovorin intravenous chemotherapy for the treatment of advanced-stage gastric carcinoma. Hepatogastroenterology. 2013;60(125):989–994.
   Google Scholar
• Yonemura Y, Ishibashi H, Li Y, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24(2):478–485.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly F, Elias D, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–2377.
   PubMed Web of Science ®Google Scholar
• Schildberg C, Weidinger T, Boxberger F, et al. Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis. World J Surg. 2014;38(2):419–425.
   Web of Science ®Google Scholar
• Wu Z, Ma S, Li X, et al. Effect of hyperthermic intraperitoneal perfusion chemotherapy in combination with intravenous chemotherapy as postoperative adjuvant therapy for advanced gastric cancer. Hepatogastroenterology. 2014;61(132):972–977.
   Google Scholar
• Canbay E, Mizumoto A, Yonemura Y, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21(4):1147–1152.
   PubMed Web of Science ®Google Scholar
• Saladino E, Fleres F, Macrì A, et al. The role of prophylactic hyperthermic intraperitoneal chemotherapy in the management of serosal involved gastric cancer. Anticancer Res. 2014;34(4):2019–2022.
   PubMed Web of Science ®Google Scholar
• Yarema R, Ohorchak M, Fetsych T, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-center retrospective study. Int J Hyperthermia. 2014;30(3):159–165.
   PubMed Web of Science ®Google Scholar
• Costa W, Coimbra F, Mello C, et al. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195.
   PubMed Web of Science ®Google Scholar
• Li C, Yan M, Lin Y, et al. Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination. J Surg Oncol. 2010;102(5):361–365.
   Web of Science ®Google Scholar
• Geng X, Liu H, Li G, et al. Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score-matched analysis. Cancer Med. 2016;5(10):2781–2791.
   PubMed Web of Science ®Google Scholar
• Graziosi L, Cantarella F, Donini A, et al. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer. Ann Ital Chir. 2013;84(5):551–556.
   Web of Science ®Google Scholar
• Coccolini F, Celotti A, Ansaloni L, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinomatosis from advanced gastric cancer-effects on overall and disease free survival. J Gastrointest Oncol. 2016;7(4):523–529.
   Google Scholar
• Kang L, Mok K, Chou N, et al. Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. J Chin Med Assoc. 2013;76(8):425–431.
   Web of Science ®Google Scholar
• Halkia E, Kopanakis N, Spiliotis J, et al. Is cholecystectomy and removal of the round ligament of the liver a necessary step in cytoreductive surgery and HIPEC, for peritoneal carcinomatosis?. Ann Ital Chir. 2015;86(4):323–326.
   Web of Science ®Google Scholar
• Berger Y, Aycart S, Mandeli J, Heskel M, Sarpel U, Labow D. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: outcomes from a single tertiary center. Surg Oncol. 2015;24(3):264–269.
   Web of Science ®Google Scholar
• American Cancer Society [webpage on the Internet]. What are the key statistics about stomach cancer?; 2014. Available from: https://www.cancer.org/cancer/stomach-cancer/about/key-statistics.html. Accessed April 19, 2017.
   Google Scholar
• Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004;8(4):454–463.
   Web of Science ®Google Scholar
• Tu Y, Tian Y, Cui S, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion for the treatment of gastric cancer: a single-center retrospective study. Int J. 2016;32(6):587–594.
   Web of Science ®Google Scholar
• Magge D, Zenati M, Choudry H, et al. Aggressive loco regional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(5):1448–1455.
   Web of Science ®Google Scholar
• Desantis M, Bernard J, Bereder J, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbeck’s Arch Surg. 2015;400(1):37–48.
   Web of Science ®Google Scholar
• Wu H, Peng K, Li Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: results from a Chinese center. Eur J Surg Oncol. 2016;42(7):1024–1034.
   Web of Science ®Google Scholar
• Graziosi L, Marino E, Donini A. Role of CRS plus HIPEC in gastric cancer peritoneal carcinomatosis. J Surg Oncol. 2015;111(2):248.
   Web of Science ®Google Scholar
• Königsrainer I, Horvath P, Struller F, Königsrainer A, Beckert S. Initial clinical experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in signet-ring cell gastric cancer with peritoneal metastases. J Gastric Cancer. 2014;14(2):117–122.
   Google Scholar
• Yang X, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: results from a Chinese center. J Surg Oncol. 2010;101(6):457–464.
   Web of Science ®Google Scholar
• Müller H, Hotopp T, Tofeili A, Wutke K. Systemic chemotherapy using FLOT – regimen combined with cytoreductive surgery plus HIPEC for treatment of peritoneal metastasized gastric cancer. Hepatogastroenterology. 2014;61(131):703–706.
   Google Scholar
• Mizumoto A, Canbay E, Yonemura Y, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012;83:642–645.
   Google Scholar
• Bhagwandin S, Naffouje S, Salti G. Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(8):2573–2577.
   Web of Science ®Google Scholar
• Macrì A, Saladino E, Famulari C, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. In Vivo. 2011;25(4):687–690.
   Web of Science ®Google Scholar
• Kim K, Chow O, Hiotis S, et al. Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg. 2014;207(1):78–83.
   Web of Science ®Google Scholar
• Votanopoulos K, Newman N, Levine E, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20(11):3497–3503.
   Web of Science ®Google Scholar
• Elias D, Gilly F, Glehen O, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456–462.
   PubMed Web of Science ®Google Scholar
• Wu X, Yuan P, Ji J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tum Biol. 2013;34(1):463–469.
   PubMedGoogle Scholar
• Seshadri R, Glehen O. The role of hyperthermic intraperitoneal chemotherapy in gastric cancer. Indian J Surg Oncol. 2016;7(2):198–207.
   Google Scholar
• Scaringi S, Kianmanesh R, Msika S, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol. 2008;34(11):1246–1252.
   Web of Science ®Google Scholar
• McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC+ EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107(6):591–596.
   PubMed Web of Science ®Google Scholar
• Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7(1):45–57.
   PubMedGoogle Scholar
• Montori G, Coccolini F, Ceresoli M, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;(2014), Article ID 912418.
   Google Scholar
• Chia C, You B, Glehen O, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23(6):1971–1979.
   PubMed Web of Science ®Google Scholar
• Topgül K, Çetinkaya M, Malazgirt Z, et al. Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: our initial experience and technical details. Ulus Cerrahi Derg. 2015;31(3):138–147.
   Google Scholar
• Gill R, Al-Adra D, Schiller D, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104(6):692–698.
   PubMed Web of Science ®Google Scholar
• Polanco P, Ding Y, Choudry H, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2015;22(5):1673–1679.
   PubMed Web of Science ®Google Scholar
• Wu X, Li Z, Ji J, et al. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. J Surg Oncol. 2015;111(7):840–847.
   Web of Science ®Google Scholar
• Hultman B, Lind P, Mahteme H, et al. Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy. Acta Oncol. 2013;52(4):824–830.
   PubMed Web of Science ®Google Scholar
• Franssen B, Tabrizian P, Sarpel U, et al. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement. Ann Surg Oncol. 2015;22(5):1639–1644.
   Web of Science ®Google Scholar
• Yang X, Li Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009;16(2):345–351.
   Web of Science ®Google Scholar
• Tsilimparis N, Bockelmann C, Hartmann J, et al. Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol. 2013;20(1):226–232.
   PubMed Web of Science ®Google Scholar
• Facchiano E, Scaringi S, Msika S, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2008;34(2):154–158.
   Web of Science ®Google Scholar
• Loggie B, Perini M, Fleming R, Russell G, Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg. 1997;63(2):137–143.
   Web of Science ®Google Scholar
• Graziosi L, Mencarelli A, Fiorucci S, et al. Gene expression changes induced by HIPEC in a murine model of gastric cancer. In Vivo. 2012;26(1):39–45.
   Web of Science ®Google Scholar
• Tang L, Duan R, Li Y, et al. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity. Mol Cancer. 2014;13(1):44–61.
   Google Scholar
• Tang L, Mei L, Li Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study. J Transl Med. 2011;9(1):53.
   Google Scholar
• Zeng X, Shi H, Wang J, Cui S, Tang H, Zhang X. Long noncoding RNA aberrant expression profiles after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of AGC ascertained by microarray analysis. Tum Biol. 2015;36(7):5021–5029.
   Google Scholar
• Zhang X, Shi H, Wang L, et al. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol. 2014;20(32):11347–11355.
   PubMed Web of Science ®Google Scholar
• Shetty S, Bathia L, Govindarajan V, Thomas P, Loggie B. Comparison of visceral sparing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin or carboplatin for diffuse malignant peritoneal mesothelioma. Am Surg. 2014;80(4):348–352.
   PubMed Web of Science ®Google Scholar
• Fleming RA, Drees J, Loggie BW, et al. Clinical significance of a NAD (P) H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics. 2002;12(1):31–37.
   Google Scholar
• Thomas P, Forse R, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis. 2011;28(8):923–932.
   PubMed Web of Science ®Google Scholar
• Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17(1):26–33.
   PubMed Web of Science ®Google Scholar
• Wang W, Seeruttun S, Zhou Z, et al. Prognostic significance of carcinoembryonic antigen staining in cancer tissues of gastric cancer patients. Ann Surg Oncol. 2016;23(4):1244–1251.
   PubMed Web of Science ®Google Scholar
• Jung M, Jeung HC, Lee SS, et al. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 2010;136(4):517–526.
   Web of Science ®Google Scholar
• Asao T, Fukuda T, Yazawa S, Nagamachi Y. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer. 1991;68(1):44–47.
   Web of Science ®Google Scholar
• Ito S, Nakanishi H, Kodera Y, Mochizuki Y, Tatematsu M, Yamamura Y. Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer. 2005;93(9):986–992.
   Web of Science ®Google Scholar
• Coccolini F, Corbella D, Ansaloni L, et al. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy. Minerva Anestesiol. 2016;82(3):310–319.
   PubMed Web of Science ®Google Scholar
• Goéré D, Gras-Chaput N, Elias D, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14(1):148–154.
   PubMedGoogle Scholar
• Stroehlein M, Jaeger M, Lindhofer H, Peschel C, Jauch K, Heiss M. Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. J Clin Oncol. 2004;22(14):2532.
   Web of Science ®Google Scholar
• Piso P, Aselmann H, von Wasielewski R, Dahlke M, Klempnauer J, Schlitt H. Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model. Eur Surg Res. 2003;35(6):470–476.
   Web of Science ®Google Scholar
• Fu Q, Meng F, Shen X, Guo R. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol. 2002;8(6):1019–1022.
   Web of Science ®Google Scholar
• Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–267.
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–2221.
   PubMed Web of Science ®Google Scholar
• Ott MG, Marmé F, Moldenhauer G, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012;130(9):2195–2203.
   PubMed Web of Science ®Google Scholar